PE20071089A1 - Compuesto heterociclico fusionado como inhibidor de tirosina quinasa - Google Patents

Compuesto heterociclico fusionado como inhibidor de tirosina quinasa

Info

Publication number
PE20071089A1
PE20071089A1 PE2006001541A PE2006001541A PE20071089A1 PE 20071089 A1 PE20071089 A1 PE 20071089A1 PE 2006001541 A PE2006001541 A PE 2006001541A PE 2006001541 A PE2006001541 A PE 2006001541A PE 20071089 A1 PE20071089 A1 PE 20071089A1
Authority
PE
Peru
Prior art keywords
alkyl
tyrosine kinase
heterocyclic compound
fused heterocyclic
chlorophenoxy
Prior art date
Application number
PE2006001541A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Kazuhiro Miwa
Masaki Seto
Hiroshi Banno
Youichi Kawakita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20071089A1 publication Critical patent/PE20071089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO HETEROCICLICO FUSIONADO DE FORMULA (Ia), EN DONDE R1a ES H; R2a ES ALQUILO(C1-C6) SUSTITUIDO CON ALQUILO (C1-C4) OPCIONALMENTE HALOGENADO CON -NR6a-CO-(CH2)n-SO2-; R3a ES H O ALQUILO(C1-C6); R4a ES HALOGENO O ALQUILO(C1-C6); R5a ES HALOGENO O ALQUILO(C1-C6); Xa ES H O HALOGENO CON LA CONDICION DE QUE SE EXCLUYA N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-(METILSULFONIL)ACETAMIDA. SON SELECCIONADOS: N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-METIL-2-(METILSULFONIL)PROPANAMIDA, N-[2-(4-{[3-CLORO-4-(3-CLOROFENOXI)FENIL]AMINO}-5H-PIRROLO[3,2-d]PIRIMIDIN-5-IL)ETIL]-2-(ETILSULFONIL)ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA TIROSINA QUINASA Y SON UTILES EN EL TRATAMIENTO DE CANCER
PE2006001541A 2005-12-02 2006-12-01 Compuesto heterociclico fusionado como inhibidor de tirosina quinasa PE20071089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005349858 2005-12-02
JP2006060648 2006-03-07

Publications (1)

Publication Number Publication Date
PE20071089A1 true PE20071089A1 (es) 2007-11-19

Family

ID=37897379

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001541A PE20071089A1 (es) 2005-12-02 2006-12-01 Compuesto heterociclico fusionado como inhibidor de tirosina quinasa

Country Status (15)

Country Link
US (1) US20100216788A1 (es)
EP (1) EP1957495A1 (es)
JP (1) JP2009517333A (es)
KR (1) KR20080084823A (es)
AR (1) AR057961A1 (es)
AU (1) AU2006319787A1 (es)
BR (1) BRPI0619911A2 (es)
CA (1) CA2631066A1 (es)
CR (1) CR10057A (es)
MA (1) MA30046B1 (es)
NO (1) NO20082870L (es)
PE (1) PE20071089A1 (es)
RU (1) RU2008126949A (es)
TW (1) TW200730527A (es)
WO (1) WO2007064045A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005250285B2 (en) * 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BRPI0720169A2 (pt) * 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
KR20100038377A (ko) 2007-06-19 2010-04-14 다케다 야쿠힌 고교 가부시키가이샤 암의 예방／치료제
TW200940546A (en) * 2008-03-03 2009-10-01 Takeda Pharmaceutical Combination drug
WO2009113560A1 (ja) * 2008-03-12 2009-09-17 武田薬品工業株式会社 縮合複素環化合物
US20140113934A1 (en) 2011-06-20 2014-04-24 E I Du Pont De Nemours And Company Heterocyclic compounds for treating helminth infections
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
HUE042111T2 (hu) * 2013-07-31 2019-06-28 Merck Patent Gmbh Piridinek, pirimidinek és pirazinok mint BTK inhibitorok, továbbá ezek alkalmazása
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU2005250285B2 (en) * 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
KR101257343B1 (ko) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
NO20082870L (no) 2008-09-01
WO2007064045A1 (en) 2007-06-07
JP2009517333A (ja) 2009-04-30
AR057961A1 (es) 2007-12-26
KR20080084823A (ko) 2008-09-19
US20100216788A1 (en) 2010-08-26
AU2006319787A1 (en) 2007-06-07
RU2008126949A (ru) 2010-01-10
CA2631066A1 (en) 2007-06-07
MA30046B1 (fr) 2008-12-01
TW200730527A (en) 2007-08-16
CR10057A (es) 2008-07-29
EP1957495A1 (en) 2008-08-20
BRPI0619911A2 (pt) 2016-08-30

Similar Documents

Publication Publication Date Title
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
UY29246A1 (es) Nuevos compuestos
PE20061367A1 (es) Nuevos derivados del fluoreno y composiciones que los contienen
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20091577A1 (es) Inhibidores de cinasa pim y metodos para su uso
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20091243A1 (es) Compuesto heterociclico fusionado
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ECSP088598A (es) Derivados de piridazinona
PE20080548A1 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de cinasa de proteina
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
AR052404A1 (es) Hidratos y polimorfos de 4-(((7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil)amino)-3- metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparacion y su uso como farmaco
SV2006002232A (es) Inhibidores bace ref. x-16940
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
PE20070179A1 (es) Derivados de purina como agonistas del receptor de adenosina a2
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
RS52601B (en) BENZOTIAZEPINE DERIVATIVES AS A RYANODIN (RYR2) RECEPTOR INHIBITOR AND THEIR USE IN THE TREATMENT OF HEART DISEASES
ATE384058T1 (de) Thiazolderivate

Legal Events

Date Code Title Description
FC Refusal